| Sensitization to gimatecan-induced apoptosis by tumor necrosis factor-related apoptosis inducing ligand in prostate carcinoma cells. | |
| | |
MedLine Citation:
|
PMID: 16438941 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Since the intrinsic resistance of prostate carcinoma likely reflects a low susceptibility to drug-induced apoptosis, in this study we explored the possibility of sensitizing prostate carcinoma cells to apoptosis by combination of TRAIL with camptothecins. Indeed, these agents are known to activate different pathways of apoptosis. Topotecan- and gimatecan induced moderate up-regulation of TRAIL-R1 and -R2 which resulted in a different cell response to the combination in androgen-independent cells (DU-145 and PC-3). In DU-145 cells apoptosis was increased by lower TRAIL concentrations and was earlier than in PC-3 cells, as shown using Annexin V-binding assay. The relative resistance of PC-3 cells to drug-induced apoptosis was associated with constitutive Akt activation, higher levels of cFLIP-L and Bcl-2, and lower levels of Bax. The different expression/activation of apoptosis-related factors appears to influence the sensitization of prostate carcinoma cells by TRAIL. Potentiation of camptothecin-induced apoptosis by TRAIL appears dependent on cooperation between extrinsic and intrinsic pathways, as documented by loss of the sensitization to apoptosis following reduction of caspase 8 after small interfering RNA transfection. The efficacy of the approach may be critically dependent on the intrinsic susceptibility to apoptosis of different tumors. These observations support that the activation of multiple signals could enhance apoptotic response and suggest the therapeutic interest of the TRAIL/camptothecin combination. |
| | |
Authors:
|
Paola Perego; Emilio Ciusani; Laura Gatti; Nives Carenini; Elisabetta Corna; Franco Zunino |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2006-01-24 |
Journal Detail:
|
Title: Biochemical pharmacology Volume: 71 ISSN: 0006-2952 ISO Abbreviation: Biochem. Pharmacol. Publication Date: 2006 Mar |
Date Detail:
|
Created Date: 2006-02-13 Completed Date: 2006-04-06 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0101032 Medline TA: Biochem Pharmacol Country: England |
Other Details:
|
Languages: eng Pagination: 791-8 Citation Subset: IM |
Affiliation:
|
Preclinical Chemotherapy and Pharmacology Unit, Department of Experimental Oncology and Laboratories, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy. paola.perego@istitutotumori.mi.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adenocarcinoma
/
drug therapy*,
metabolism,
pathology Antineoplastic Agents, Phytogenic / pharmacology* Apoptosis / drug effects*, genetics Apoptosis Regulatory Proteins / pharmacology* Camptothecin / analogs & derivatives*, pharmacology Caspase 8 Caspases / genetics, metabolism Cell Line, Tumor Cell Survival / drug effects Dose-Response Relationship, Drug Drug Combinations Drug Screening Assays, Antitumor Drug Synergism Gene Silencing / drug effects Genetic Vectors Humans Male Membrane Glycoproteins / pharmacology* Prostatic Neoplasms / drug therapy*, metabolism, pathology RNA, Small Interfering / administration & dosage, genetics Receptors, TNF-Related Apoptosis-Inducing Ligand Receptors, Tumor Necrosis Factor / metabolism TNF-Related Apoptosis-Inducing Ligand Topotecan / pharmacology Transfection Tumor Necrosis Factor-alpha / pharmacology* Up-Regulation / drug effects |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents, Phytogenic; 0/Apoptosis Regulatory Proteins; 0/Drug Combinations; 0/Membrane Glycoproteins; 0/RNA, Small Interfering; 0/Receptors, TNF-Related Apoptosis-Inducing Ligand; 0/Receptors, Tumor Necrosis Factor; 0/ST 1481; 0/TNF-Related Apoptosis-Inducing Ligand; 0/TNFRSF10A protein, human; 0/TNFRSF10B protein, human; 0/TNFSF10 protein, human; 0/Tumor Necrosis Factor-alpha; 123948-87-8/Topotecan; 7689-03-4/Camptothecin; EC 3.4.22.-/CASP8 protein, human; EC 3.4.22.-/Caspase 8; EC 3.4.22.-/Caspases |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Pyridine N-oxide derivatives inhibit viral transactivation by interfering with NF-kappaB binding.
Next Document: Sensory suppression during shifts of attention between surfaces in transparent motion.